Key result
The fixed combination of rosuvastatin, lisinopril, and amlodipine effectively controls arterial hypertension and hypercholesterolemia, increasing therapy adherence and reducing cardiovascular risk.
Why the study?
Does a fixed combination of rosuvastatin, lisinopril, and amlodipine improve adherence and reduce cardiovascular complications in patients with hypercholesterolemia and arterial hypertension?
Does a fixed combination of rosuvastatin, lisinopril, and amlodipine improve adherence and reduce cardiovascular complications in patients with hypercholesterolemia and arterial hypertension?
A fixed-dose combination of lisinopril, amlodipine, and rosuvastatin offers a convenient strategy to simultaneously manage hypertension and hypercholesterolemia, potentially improving adherence and reducing cardiovascular risk.
May aid adherence with multicomponent therapy; leaves open outcome benefits in prevention.
The prevalence of multicomponent therapy in treatment of cardiovascular diseases makes fixed combinations of drugs very useful. The fixed combination of rosuvastatin with ACE inhibitor lisinopril and calcium antagonist amlodipine allows to control effectively two main cardiovascular risk factors: hypercholesterolemia and arterial hypertension. The efficacy of each of the components and their combined administration in primary and secondary prevention of cardiovascular disease has been demonstrated in clinical studies. The convenience of several drugs combination in a single tablet increases adherence to therapy facilitating regular intake of all treatment components and reliably reducing the risk of cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Семенова et al. (2017) conducted a review in Cardiovascular disease, arterial hypertension, hypercholesterolemia. Fixed combination of lisinopril, amlodipine, and rosuvastatin was evaluated. The fixed combination of rosuvastatin, lisinopril, and amlodipine effectively controls arterial hypertension and hypercholesterolemia, increasing therapy adherence and reducing cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: